Unknown

Dataset Information

0

Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity.


ABSTRACT: Tamoxifen is administered for estrogen receptor positive (ER+) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER+ breast cancer than five years of such treatment. Tamoxifen was also approved by the FDA as a chemopreventive agent for those deemed at high risk for the development of breast cancer. The side effects are of substantial concern because of these extended methods of tamoxifen administration. In this study, we found that anordrin, marketed as an antifertility medicine in China, inhibited tamoxifen-induced endometrial epithelial cell mitosis and NAFLD in mouse uterus and liver as an anti-estrogenic and estrogenic agent, respectively. Additionally, compared with tamoxifen, anordiol, the active metabolite of anordrin, weakly bound to the ligand binding domain of ER-?. Anordrin did not regulate the classic estrogen nuclear pathway; thus, it did not affect the anti-tumor activity of tamoxifen in nude mice. Taken together, these data suggested that anordrin could eliminate the side effects of tamoxifen without affecting its anti-tumor activity.

SUBMITTER: Gu W 

PROVIDER: S-EPMC5339706 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity.

Gu Wenwen W   Xu Wenping W   Sun Xiaoxi X   Zeng Bubing B   Wang Shuangjie S   Dong Nian N   Zhang Xu X   Chen Chengshui C   Yang Long L   Chen Guowu G   Xin Aijie A   Ni Zhong Z   Wang Jian J   Yang Jun J  

Scientific reports 20170307


Tamoxifen is administered for estrogen receptor positive (ER<sup>+</sup>) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER<sup>+</sup> breast cancer than five years of such treatment. Tamoxifen was also approved by the FDA as a chemopreventive agent for those deemed at high risk for the development of breast cancer. The side effects are of substantial  ...[more]

Similar Datasets

| S-EPMC7849892 | biostudies-literature
| S-EPMC4589558 | biostudies-literature
| S-EPMC8798170 | biostudies-literature
| S-EPMC6282113 | biostudies-literature
2021-02-01 | GSE158960 | GEO
| S-EPMC7467771 | biostudies-literature
| S-EPMC5068814 | biostudies-literature
| S-EPMC4943390 | biostudies-literature
| S-EPMC8316332 | biostudies-literature
| S-EPMC4396041 | biostudies-literature